Posted by AGORACOM-JC
at 10:16 AM on Thursday, December 27th, 2018
Filed a Form S-1 Registration Statement with the U.S. Securities and Exchange Commission (SEC)
The Company’s registration statement included a prospectus pertaining to the resale of up to 500,000,000 shares of its Common Shares, issuable to K&J Funds, LLC, a selling stockholder, pursuant to a “put rightâ€
Agreement permits the Company to “put†up to ten million dollars ($10,000,000) in shares of its common stock to K&J over a period of up to thirty-six months or until $10,000,000 of such shares have been “put.â€
ESCONDIDO, Calif., Dec. 27, 2018 – MARIJUANA COMPANY OF AMERICA INC. (“MCOA†or the “Companyâ€) (OTC: MCOA), an innovative hemp and cannabis corporation, is very pleased to announce that it has filed a Form S-1 Registration Statement with the U.S. Securities and Exchange Commission (SEC). This is an important step in helping the Company to raise the necessary capital to fund its projects and expand its operations in 2019.
The Company’s registration statement included a prospectus pertaining
to the resale of up to 500,000,000 shares of its Common Shares,
issuable to K&J Funds, LLC (“K&Jâ€), a selling stockholder,
pursuant to a “put right†under an investment agreement (the “Investment
Agreementâ€), dated December 20, 2018, that the Company entered into
with K&J. The Investment Agreement permits the Company to “put†up
to ten million dollars ($10,000,000) in shares of its common stock to
K&J over a period of up to thirty-six months or until $10,000,000 of
such shares have been “put.â€
The total amount of shares of common stock that can be sold in the
prospectus would constitute approximately 20.08% of the Company’s issued
and outstanding common stock, assuming that the selling security holder
will sell all of the shares offered for sale.
Don Steinberg, CEO stated: “We are extremely excited to have K&J
as our financial partner for MCOA. They understand the history of the
Company, our clear vision for the future and the enormous market within
our reach, as reflected by this substantial commitment. This funding
will give us the capital needed to expand our hempSMART brand into
Europe and Asia in 2019 and prepare for our continued expansion into the
hemp industry as a grower and processor in California and other areas.”
“We are happy that we are moving away from relying on convertible
debt financing with variably priced conversion terms that are less
favorable to our shareholders to equity financing. This will show the
strength of our market capitalization and help to build a stronger
balance sheet as we continue to execute our aggressive growth plans for
2019. I believe our shareholders will begin to fully appreciate our
long-term strategy as we continue to realize an increase in revenue from
our significant investments over the last couple of yearsâ€, said the
Company’s CFO, Jesus Quintero.
This is the culmination of several steps including the filing of Form
10, filing all SEC quarterly and annual filings timely, completing
several financial statement audits by a PCAOB registered firm,
appointing independent directors and uplisting to the OTCQB. The Company
is executing its business plan and will continue to do so with its
operational initiatives in 2019 with the necessary capital in place.
A registration statement relating to these securities has been filed
with the Securities and Exchange Commission but has not yet become
effective. The registration statement is contingent upon it being made
effective after review by the SEC. This press release is not an offer
for the sale of securities in the United States or in any other
jurisdiction where such offer is prohibited, and such securities may not
be offered or sold in the United States absent an SEC effective
registration or an exemption from registration under the United States
Securities Act of 1933, as amended.
About Marijuana Company of America, Inc. MCOA is a corporation which participates in: (1) product research and development of legal hemp-based consumer products under the brand name “hempSMART™â€, that targets general health and well-being; (2) an affiliate marketing program to promote and sell its legal hemp-based consumer products containing CBD; (3) leasing of real property to separate business entities engaged in the growth and sale of cannabis in those states and jurisdictions where cannabis has been legalized and properly regulated for medicinal and recreations use; and, (4) the expansion of its business into ancillary areas of the legalized cannabis and hemp industry, as the legalized markets and opportunities in this segment mature and develop.
About Our hempSMART Products Containing CBD The
United States Food and Drug Administration (FDA) has not recognized CBD
as a safe and effective drug for any indication. Our products containing
CBD derived from industrial hemp are not marketed or sold based upon
claims that their use is safe and effective treatment for any medical
condition as drugs or dietary supplements subject to the FDA’s
jurisdiction.
Forward Looking Statements This
news release contains “forward-looking statements” which are not purely
historical and may include any statements regarding beliefs, plans,
expectations or intentions regarding the future. Such forward-looking
statements include, among other things, the development, costs and
results of new business opportunities and words such as “anticipate”,
“seek”, intend”, “believe”, “estimate”, “expect”, “project”, “plan”, or
similar phrases may be deemed “forward-looking statements” within the
meaning of the Private Securities Litigation Reform Act of 1995. Actual
results could differ from those projected in any forward-looking
statements due to numerous factors. Such factors include, among others,
the inherent uncertainties associated with new projects, the future U.S.
and global economies, the impact of competition, and the Company’s
reliance on existing regulations regarding the use and development of
cannabis-based products. These forward-looking statements are made as of
the date of this news release, and we assume no obligation to update
the forward-looking statements, or to update the reasons why actual
results could differ from those projected in the forward-looking
statements. Although we believe that any beliefs, plans, expectations
and intentions contained in this press release are reasonable, there can
be no assurance that any such beliefs, plans, expectations or
intentions will prove to be accurate. Investors should consult all of
the information set forth herein and should also refer to the risk
factors disclosure outlined in our annual report on Form 10-12G, our
quarterly reports on Form 10-Q and other periodic reports filed from
time-to-time with the Securities and Exchange Commission. For more
information, please visit www.sec.gov.
For more information, please visit the Company’s websites at:
Tags: Hemp, Marijuana, Marijuana Stocks, weed Posted in Marijuana Company of America | Comments Off on Marijuana Company of America $MCOA Announces Filing of Registration Statement on Form S-1 to Receive up to $10M to Fund Expansion $AERO $CBDS $CGRW $APH.ca $GBLX
Posted by AGORACOM-JC
at 8:14 AM on Friday, December 21st, 2018
Extremely optimistic about the Company’s current and future endeavors with the recent passing of the 2018 Farm Bill on December 20 after an 87 to 13 majority vote in the Senate and a 369 to 47 majority vote in the House and final approval by President Trump.
Escondido, California–(December 21, 2018) – MARIJUANA COMPANY OF AMERICA INC.(OTCQB: MCOA) (“MCOA” or the “Company“), an innovative hemp and cannabis corporation, is extremely optimistic about the Company’s current and future endeavors with the recent passing of the 2018 Farm Bill on December 20 after an 87 to 13 majority vote in the Senate and a 369 to 47 majority vote in the House and final approval by President Trump.
The beginning of 2019 boasts an expectational opportunity for the
hemp industry generally. The industrial hemp plant and its extracts,
including Cannabidiol (CBD), containing less than 0.3 percent of THC,
will be removed from its shadowy label as a Schedule 1 Drug and will be
made a legal commodity to cultivate and distribute throughout the United
States, subject to farmers’ compliance with provisions of the Farm
Bill, associated federal regulations, associated state regulations and
licensing.
According to the Brightfield Group’s Hemp CBD Report of 2018, “With
the passing of the 2018 Farm Bill … the market is expected to grow
exponentially, outpacing the rest of the cannabis market combined to
reach $22 billion by 2022.”
The Company owns and operates a vertically integrated portfolio
powered by its Industrial CBD hemp farm in Scio, Oregon, and the
manufacturing and distribution of Industrial hemp derived CBD products
via its wholly owned subsidiary hempSMART™. The passing of the 2018 Farm
Bill will allow MCOA to rapidly scale its acreage of high yielding
Industrial CBD hemp and increase its market share involving the sale of
its CBD based product formulations.
Certain roadblocks currently facing our industry are expected to
hopefully be removed soon, such as our access to federal insured banking
systems, merchant processing, insurance, and ability to register
intellectual property. One of the most significant benefits is that this
new bill will help to lower federal income tax as Section 280E of the
Internal Revenue Code will no longer apply to the sale of CBD. All of
these developments will help to significantly open the Company’s
distribution networks and materially enhance the Company’s financial
performance.
Donald Steinberg, Chief Executive Officer of the Company, stated,
“MCOA and our subsidiaries are anxious to take full advantage of
opportunities that passage of the Farm Bill provides to the Company.
2019 will be a year of international expansion for our hempSMART product
line. We believe the new Farm Bill may also establish a precedence for
other countries worldwide to adopt similar laws, which will allow us the
opportunity to expand more internationally.”
MCOA is a corporation which participates in: (1) product research and
development of legal hemp-based consumer products under the brand name
“hempSMART™”, that targets general health and well-being; (2) an
affiliate marketing program to promote and sell its legal hemp-based
consumer products containing CBD; (3) leasing of real property to
separate business entities engaged in the growth and sale of cannabis in
those states and jurisdictions where cannabis has been legalized and
properly regulated for medicinal and recreations use; and, (4) the
expansion of its business into ancillary areas of the legalized cannabis
and hemp industry, as the legalized markets and opportunities in this
segment mature and develop.
About Our hempSMART Products Containing CBD The
United States Food and Drug Administration (FDA) has not recognized CBD
as a safe and effective drug for any indication. Our products containing
CBD derived from industrial hemp are not marketed or sold based upon
claims that their use is safe and effective treatment for any medical
condition as drugs or dietary supplements subject to the FDA’s
jurisdiction.
Forward Looking Statements This news
release contains “forward-looking statements” which are not purely
historical and may include any statements regarding beliefs, plans,
expectations or intentions regarding the future. Such forward-looking
statements include, among other things, the development, costs and
results of new business opportunities and words such as “anticipate”,
“seek”, intend”, “believe”, “estimate”, “expect”, “project”, “plan”, or
similar phrases may be deemed “forward-looking statements” within the
meaning of the Private Securities Litigation Reform Act of 1995. Actual
results could differ from those projected in any forward-looking
statements due to numerous factors. Such factors include, among others,
the inherent uncertainties associated with new projects, the future U.S.
and global economies, the impact of competition, and the Company’s
reliance on existing regulations regarding the use and development of
cannabis-based products. These forward-looking statements are made as of
the date of this news release, and we assume no obligation to update
the forward-looking statements, or to update the reasons why actual
results could differ from those projected in the forward-looking
statements. Although we believe that any beliefs, plans, expectations
and intentions contained in this press release are reasonable, there can
be no assurance that any such beliefs, plans, expectations or
intentions will prove to be accurate. Investors should consult all of
the information set forth herein and should also refer to the risk
factors disclosure outlined in our annual report on Form 10-12G, our
quarterly reports on Form 10-Q and other periodic reports filed from
time-to-time with the Securities and Exchange Commission. For more
information, please visit www.sec.gov.
For more information, please visit the Company’s websites at:
Tags: Marijuana, weed Posted in Marijuana Company of America | Comments Off on Marijuana Company of America $MCOA Poised for Significant Growth with Passage of Farm Bill $AERO $CBDS $CGRW $APH.ca $GBLX $ACG $ACB $WEED.ca $HIP.ca
Posted by AGORACOM-JC
at 12:48 PM on Monday, December 17th, 2018
SPONSOR: North Bud Farms Inc. (NBUD:CSE) Sustainable low cost, high
quality cannabinoid production and procurement focusing on both
bio-pharmaceutical development and Cannabinoid Infused Products. Click Here For More Information
Two months after the legalization of recreational cannabis, is
the new legislation meeting its objectives? CTVNews.ca takes a look at
some of the Cannabis Act’s key goals.
Two months after recreational cannabis was legalized, Canada’s new
pot regime is still working out kinks in the supply chain and the
enforcement of new rules.
Before the cannabis legislation came into force, the federal
government listed its key objectives for the historic shift. Those goals
include keeping cannabis “out of the hands of children and youth,â€
curbing illegal marijuana sales, and ensuring a safe supply of quality
pot across the country.
More than 60 days after the first legal cannabis sales were made on
Oct. 17, are those objectives being met? CTVNews.ca takes a look at how
reality measures up against some of the government’s main promises.
Keep cannabis away from children
The Cannabis Act
states that only adults aged 18 or older can legally purchase, possess
and grow small amounts of weed. Provinces and territories were allowed
to impose their own age restrictions, and the majority have set 19 as
the legal age.
Quebec’s new Coalition Avenir Quebec government made good on its
election campaign promise and tabled legislation that would raise the
province’s legal cannabis consumption age to 21 – the highest in Canada.
Of course, those age restrictions don’t guarantee that younger teens
and kids won’t be getting their hands on pot. It remains to be seen
whether legalization will actually reduce cannabis consumption among
minors.
Reduce number of Canadians with criminal records
One of the main pillars of the Cannabis Act is reducing the burden on
the Canadian justice system by eliminating criminal charges for simple
pot possession. But what about those who were charged or convicted of
the crime before Oct. 17, 2018?
In October, the federal government announced its intention to issue
pardons to Canadians who have criminal records for possession of 30
grams of cannabis or less.
The legislation “to make things fairerâ€
was expected to be tabled before the end of 2018, but that did not
happen before MPs wrapped things up in Ottawa for the holiday break.
When it eventually becomes law, those eligible for pardons will be able
to apply as soon as the law is in effect, with no waiting period or
application fees.
The Liberal government, however, has been criticized for not opting
to expunge the criminal records of Canadians convicted of simple
possession. An expungement would remove any record of a criminal
conviction, while a pardon seals the record but does not erase it.
Safe supply of cannabis
The federal government pledged to “establish and enforce a strict
system of production, distribution and sales†of cannabis, with a focus
on regulation of quality and safety.
But some Canadians have reported receiving mouldy cannabis.
One cannabis manufacturer, RedeCan, recalled its B.E.C. strain in November after receiving reports of mould in some products sold in Ontario and British Columbia.
Under federal regulations, cannabis producers have to keep a sample of every batch they send to market.
Eliminate illicit pot sales
This is another long-term objective of the Cannabis Act, but numerous
hiccups in the legal cannabis supply chain have done little to curb
distribution of illegal weed.
Despite numerous warnings to illegal cannabis stores – and police
raids in several cities across the country – some illicit dispensaries say they’ve been busier than ever since Oct. 17.
Some consumers told The Canadian Press they continued to get their
weed from illegal dispensaries or elsewhere because of delivery delays
like the ones that plagued the Ontario Cannabis Store (OCS) in the first
month of legalization.
The OCS attributed delays to high demand for cannabis products, but
the nationwide rotating strikes by Canada Post workers were also blamed
for slow deliveries.
The online OCS is currently the only legal outlet for recreational
cannabis in Ontario, with brick-and-mortar stores expected in 2019.
In the first few weeks of business, the office of the
Ontarioombudsman received more than 1,000 complaints about the OCS,
related to delivery delays, poor customer service and issues with
billing.
By the third week of November, the provincial government said the OCS had eliminated its backlog and deliveries were “back on track.â€
British Columbia, Alberta, Manitoba, Saskatchewan, Quebec, Nova
Scotia and New Brunswick also reported varying degrees of cannabis
shortages.
New Brunswick was forced to temporarily close more than half its stores in early November, and the Quebec Cannabis Corporation had to reduce its store opening hours due to shortages.
Access to medical cannabis
One of the government’s principal objectives in legalizing
recreational pot was to provide “access to quality-controlled cannabis
for medical purposes.â€
But medical cannabis users have complained that, since Oct. 17,
they’ve experienced persistent product shortages and shipment delays.
Users of medical cannabis can only buy products from specific
licensed producers if they want their health insurance to cover the
cost. When their preferred strain or product is not available, they
either have to go without, or pay out of pocket for products from a
recreational pot retailer.
Health Canada admitted last month
that there have been localized shortages of medical cannabis since
legalization, and said they are expected to continue for months.
Protecting public health and safety
The federal government has vowed to strengthen laws aimed at
punishing “more serious cannabis offences,†including selling and
distributing pot to children and youth, and driving under the influence
of cannabis.
Legislation known as Bill C-46
sets prohibited blood drug concentrations of THC, the main psychoactive
compound of cannabis, for drivers. It also outlines penalties for drug
offences, which range from fines to imprisonment, depending on the
severity and number of offences committed.
As a result of Bill C-46, police can now demand a sample of saliva
for roadside drug screening. However, the only device approved for
roadside drug testing in Canada has been met with criticism, with some
police forces even saying they will not be using it at all.
Critics say the Drager DrugTest 5000
doesn’t work in sub-zero temperatures, is too bulky for roadside tests
and takes too long to produce a sample. But the federal government has
defended the device, saying its approval was based on scientific
recommendations of the Drugs and Driving Committee.
Bill C-46 also amended Canada’s drunk-driving laws to allow police officers to conduct mandatory roadside alcohol breath tests without requiring a suspicion that the driver had been drinking.
With files from CTVNews.ca’s Rachel Aiello and The Canadian Press
Tags: Marijuana, stocks, tsx, tsx-v, weed Posted in North Bud Farms Inc | Comments Off on North Bud Farms Inc. $NBUD.ca – Cannabis report card: How’s the legal pot regime working for Canadians? $ACB $WEED.ca $HIP.ca
Posted by AGORACOM-JC
at 8:33 AM on Tuesday, December 11th, 2018
Announced the launch of a new corporate hempSMART™ website and marketing platform for its associates
By implementing this new associate platform, hempSMART’s customers now have the ability to subscribe monthly to our products creating a pathway to generate an annuity stream of monthly reoccurring revenue with minimal follow up.
Escondido, California–(December 11, 2018) – MARIJUANA COMPANY OF AMERICA INC.(OTC Pink: MCOA) (“MCOA” or the “Company“), an innovative hemp and cannabis corporation, is pleased to announce the launch of a new corporate hempSMART™ website and marketing platform for its associates.
By implementing this new associate platform, hempSMART’s customers
now have the ability to subscribe monthly to our products creating a
pathway to generate an annuity stream of monthly reoccurring revenue
with minimal follow up. Since Q3, the Company has already seen an
increase in associate signups with the new marketing platform and it is
expected that Q4 of 2018 will feature the highest generated revenue of
the Company’s history.
The new hempSMART platform is focused on incentivizing our current
and future associates to take full advantage of our newly structured
compensation plan. MCOA anticipates an increase in sales and a
continuous influx of associate signups towards year end.
Donald Steinberg, MCOA’s CEO, stated, “As we start the hempSMART
global expansion, it was imperative to have a platform able to
facilitate a large number of affiliates with different currencies and
languages. This platform provides our affiliates with the latest in
marketing software to allow them to take advantage of all social media
outlets. With my background in establishing large global marketing and
distribution companies, I am confident this platform will allow us to
focus on growth. We have a good solid company with an excellent team,
and we have developed great industrial hemp based CBD infused products
which are garnering acclaim from many sources. In addition, we have an
affiliate marketing program that is structured to provide long term
residual income from a global marketplace. It is for all of these
reasons that I believe our company is now set for long term growth.”
The Company is also highly optimistic about the imminent passage of
the Farm Bill by Congress, which will help the Company obtain better
banking relationships as well as give more overall awareness to the
hempSMART brand and products.
MCOA is a corporation which participates in: (1) product research and
development of legal hemp-based consumer products under the brand name
“hempSMART™”, that targets general health and well-being; (2) an
affiliate marketing program to promote and sell its legal hemp-based
consumer products containing CBD; (3) leasing of real property to
separate business entities engaged in the growth and sale of cannabis in
those states and jurisdictions where cannabis has been legalized and
properly regulated for medicinal and recreational use; and, (4) the
expansion of its business into ancillary areas of the legalized cannabis
and hemp industry, as the legalized markets and opportunities in this
segment mature and develop.
About Our hempSMART Products Containing CBD
The United States Food and Drug Administration (FDA) has not
recognized CBD as a safe and effective drug for any indication. Our
products containing CBD derived from industrial hemp are not marketed or
sold based upon claims that their use is safe and effective treatment
for any medical condition as drugs or dietary supplements subject to the
FDA’s jurisdiction.
Forward Looking Statements
This news release contains “forward-looking statements” which are
not purely historical and may include any statements regarding beliefs,
plans, expectations or intentions regarding the future. Such
forward-looking statements include, among other things, the development,
costs and results of new business opportunities and words such as
“anticipate”, “seek”, intend”, “believe”, “estimate”, “expect”,
“project”, “plan”, or similar phrases may be deemed “forward-looking
statements” within the meaning of the Private Securities Litigation
Reform Act of 1995. Actual results could differ from those projected in
any forward-looking statements due to numerous factors. Such factors
include, among others, the inherent uncertainties associated with new
projects, the future U.S. and global economies, the impact of
competition, and the Company’s reliance on existing regulations
regarding the use and development of cannabis-based products. These
forward-looking statements are made as of the date of this news release,
and we assume no obligation to update the forward-looking statements,
or to update the reasons why actual results could differ from those
projected in the forward-looking statements. Although we believe that
any beliefs, plans, expectations and intentions contained in this press
release are reasonable, there can be no assurance that any such beliefs,
plans, expectations or intentions will prove to be accurate. Investors
should consult all of the information set forth herein and should also
refer to the risk factors disclosure outlined in our annual report on
Form 10-12G, our quarterly reports on Form 10-Q and other periodic
reports filed from time-to-time with the Securities and Exchange
Commission. For more information, please visit www.sec.gov.
For more information, please visit the Company’s websites at:
Tags: Hemp, moca, weed Posted in All Recent Posts, Marijuana Company of America | Comments Off on Marijuana Company of America $MCOA Announces New hempSMART(TM) Website and Sales Platform $AERO $CBDS $CGRW $APH.ca $GBLX $ACG $ACB $WEED.ca $HIP.ca
Posted by AGORACOM-JC
at 8:28 AM on Monday, December 3rd, 2018
Announces the delivery of twenty containers, more than 1.7 million cans of its product Hemp Energy Drink,
the first hemp energy drink in Canada, to meet growing demand in Canada and to make Hemp Energy Drink available across all regions of the country.
ORLEANS, Ontario, Dec. 03, 2018 — Tetra Natural Heath, a subsidiary of Tetra Bio-Pharma (TSX VENTURE: TBP) (OTCQB: TBPMF), announces the delivery of twenty containers, more than 1.7 million cans of its product Hemp Energy Drink, the first hemp energy drink in Canada, to meet growing demand in Canada and to make Hemp Energy Drink available across all regions of the country.
Hemp Energy Drink available in 3 flavours: Classic, Mango and Raspberry
Canadian consumers appreciate the qualities of Hemp Energy Drink (www.hempenergydrink.ca) that contains fewer calories and more natural ingredients than other energy drinks, and the product will be available soon everywhere in Canada in three flavors: classic, mango and raspberry.
“We are very pleased with the consumer interest for the Hemp Energy Drink since its launch. Through the agreements we have with our distribution partners, their drive and the strategy we are implementing, Canadians will soon be able to appreciate the three flavors of our cool, fresh, light, natural and 100% legal beverage,” said Richard Giguère, CEO of Tetra Natural Health.
“This 20-container delivery combined with the deployment of our distribution strategy represents an important step in our market development plan for this product over the next year. Thanks to the characteristics of our energy drink and its nutritional elements, we are confident that the Hemp Energy Drink will generate a continued enthusiasm among consumers across Canada,” added Richard Giguère.
Guy Chamberland, President and CEO of Tetra Bio-Pharma stated, “With its Hemp Energy Drink business, Tetra Natural Health will allow the corporation to achieve significant orders and sales over the coming year. These orders demonstrate that the new team has established a viable natural health and wellness product business that will translate into significant revenues for the coming fiscal year, starting in Q1 2019.”
About Tetra Natural Health
Tetra Natural Health inc. is a subsidiary of Tetra Bio-Pharma inc. that focuses on identification, development and marketing of hemp or cannabis-based natural health products, or cannabinoids-based products authorized for sale by Health Canada.
About Tetra Bio-Pharma Tetra Bio-Pharma (TSX-V: TBP) (OTCQB: TBPMF) is a biopharmaceutical leader in cannabinoid- based drug discovery and development with a Health Canada approved, and FDA reviewed, clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. The Company has several subsidiaries engaged in the development of an advanced and growing pipeline of Bio Pharmaceuticals, Natural Health and Veterinary Products containing cannabis and other medicinal plant-based elements. With patients at the core of what we do, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies.
For more information visit: www.tetrabiopharma.com
Source: Tetra Bio-Pharma
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-looking statements
Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company’s research and development strategies, including this trial, the ability to obtain orphan drug status, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing of clinical trials, the timing and outcomes of regulatory or intellectual property decisions, the success of various product launches including the one discussed in this release, and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. While no definitive documentation has yet been signed by the parties and there is no certainty that such documentation will be signed. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.
For more information, please contact:
Richard Giguère
CEO
Tetra Natural Health
T 348-899-7575 ext.210 [email protected]
Media Contact
Daniel Granger
ACJ Communication
T. 514Â 840-7990
M. 514Â 232 1556 [email protected]
Charlotte Blanche
T. 514 840-1235 poste 7772
M. 514 914-0593 [email protected]
Posted by AGORACOM-JC
at 5:33 PM on Friday, November 30th, 2018
With increased cash Tetra will ramp up Drug Development Activities
Tetra issued to Aphria (6,900,000) units,
with each unit being comprised of one Class A common share of Tetra (a “Common Shareâ€) and one Common Share purchase warrant (a “Warrantâ€), at a price of $1.03 per unit
ORLEANS, Ontario, Nov. 30, 2018 — Tetra Bio-Pharma Inc (“Tetra†or “TBPâ€), (TSX VENTURE: TBP) (OTCQB: TBPMF), has closed a private placement of units (the “Private Placementâ€) with its strategic partner Aphria Inc. (“Aphriaâ€) (TSX: APHA) (NYSE: APHA). Under the Private Placement, Tetra issued to Aphria (6,900,000) units (the “Unitsâ€), with each unit being comprised of one Class A common share of Tetra (a “Common Shareâ€) and one Common Share purchase warrant (a “Warrantâ€), at a price of $1.03 per unit, which is the closing price of the Common Shares on the TSX Venture Exchange on November 28, 2018, for gross proceeds of $7,107,000. Each warrant will entitle Aphria to purchase one full common share at a price of $1.29 per Common Share for a period of 36 months expiring November 2021 subject to acceleration in certain circumstances. As part of the transaction, and in order for Aphria to attain 19.9%, Tetra Co-Founders, Andre Rancourt and Dr. Guy Chamberland, CEO and CSO of Tetra have agreed to sell 5 million shares each to Aphria. Following this sale Dr. Chamberland and Mr. Rancourt will continue to hold 5 million shares each as the company moves forward.
Dr. Guy Chamberland, CEO and CSO of Tetra Bio-Pharma stated, “Aphria has been a major strategic partner since the inception of Tetra. Their decision to substantially increase their holding in our company illustrates their confidence in our business model which is focused on taking a pharmaceutical pathway to the commercialization of cannabis and cannabinoid-derived products. The Aphria investment will enable Tetra to increase drug development activities, including in the USA, over the coming months. As for the sale of my shares to Aphria, this divestiture was done to accommodate Aphria and for personal tax and estate planning purposes following the sale of PhytoPain Pharma Inc., earlier this year. I continue to be one of the company’s major shareholders, and I am fully committed to executing Tetra’s business plan.â€
“As a leader in the global cannabis industry, Aphria is committed to fostering the research, development and commercialization of medical cannabis treatments and applications with our valued strategic partners,†said Vic Neufeld, CEO of Aphria. “With this investment, we are pleased to deepen our long-standing relationship with Tetra Bio-Pharma as they pursue critical research and clinical trials with the potential to bring notable advances to cannabis and cannabinoid-derived pharmaceutical products.â€
About Aphria Inc.
Aphria is a leading global cannabis company driven by an unrelenting commitment to our people, product quality, and innovation. Headquartered in Leamington, Ontario – the green house capital of Canada – Aphria has been setting the standard for the low-cost production of safe, clean, and pure pharmaceutical-grade cannabis at scale, grown in the most natural conditions possible. Focusing on untapped opportunities and backed by the latest technologies, Aphria is committed to bringing breakthrough innovation to the global cannabis market. The Company’s portfolio of brands is grounded in expertly-researched consumer insights designed to meet the needs of every consumer segment. Rooted in our founders’ multi-generational expertise in commercial agriculture, Aphria dries sustainable long-term shareholder value through a diversified approach to innovation, strategic partnerships, and global expansion, with a presence in more than 10 countries across 5 continents.
About Tetra Bio-Pharma Tetra Bio-Pharma (TSX-V: TBP) (OTCQB: TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and development with a Health Canada approved, and FDA reviewed, clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. The Company has several subsidiaries engaged in the development of an advanced and growing pipeline of Bio Pharmaceuticals, Natural Health and Veterinary Products containing cannabis and other medicinal plant-based elements. With patients at the core of what we do, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-looking statements Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company’s research and development strategies, the success of this joint venture, the ability to obtain orphan drug status, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing of clinical trials, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. While no definitive documentation has yet been signed by the parties and there is no certainty that such documentation will be signed. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.
For further information, please contact Tetra Bio-Pharma Inc.
Robert Bechard
Executive Vice-President Corporate Development and Licensing
514-817-2514 [email protected]
Posted by AGORACOM-JC
at 8:25 AM on Tuesday, November 27th, 2018
Provide an update on the harvest at their high yielding CBD hemp project in Scio, Oregon.
2018 Scio cultivation consisted of 33 acres of high yielding CBD hemp (utilizing six different cultivars with an expected CBD content ranging from 6% to 12%), grown in an orchard style cultivation on the property.
Escondido, California–(November 27, 2018) – MARIJUANA COMPANY OF AMERICA INC. (OTC Pink: MCOA) (“MCOA” or the “Company“), an innovative hemp and cannabis corporation, and its joint venture partner Global Hemp Group (CSE: GHG) (OTC Pink: GBHPF)Â (FSE: GHG) are pleased to provide an update on the harvest at their high yielding CBD hemp project in Scio, Oregon.
The 2018 Scio cultivation consisted of 33 acres of high yielding CBD hemp (utilizing six different cultivars with an expected CBD content ranging from 6% to 12%), grown in an orchard style cultivation on the property. With the help of near perfect weather in the region that extended the harvest period by several weeks, the hemp crop had the opportunity to grow to full maturity, allowing the team to completely harvest all of the plants before the fall rains began in the valley. For pictures from this season’s cultivation, please visit the Scio project page on MCOA’s corporate website here: http://marijuanacompanyofamerica.com/scio-oregon/
Innovation was the key to overcoming various challenges throughout the year, but the team in Scio was able to find solutions when required. Our team consists of a number of talented crew members trained in a variety of skill sets, including metal fabrication, fine carpentry, and large equipment operation. With the help of a number of knowledgeable advisors, the team set up, built, and operated the project themselves.
This year’s harvest consisted of approximately 37,000 high yielding CBD hemp plants producing 24 tons of biomass. Harvesting this year was done by hand, making it extremely labor intensive and time consuming. However, the team developed a number of solutions that will automate both the harvesting and planting for next year’s crop. Ultimately, the goal is to completely automate these processes, making it more efficient and less costly to complete. The team has now begun working on prototypes to automate the harvesting processes and expect to have machinery ready for use next season.
A number of different drying techniques were employed with this year’s harvest. In the end, “old school” hanging techniques proved to be the most effective and efficient. Drying took place in the farm’s larger 20-foot-high, 4,000 sq. ft. greenhouse which allowed for an increased quantity of plants being dried at any one time. Drying took approximately 36 to 48 hours to achieve the levels required for storage and ultimately extraction. With each successive batch of drying, techniques were improved to increase the volume of biomass being dried in the greenhouse, while decreasing the time that it took to hang and dry it.
Results
The drying process for all of the hemp harvested is now complete, and is stored awaiting further processing. The farm produced 48,000 pounds of dried biomass, which is stockpiled in quarter ton super sacks, stacked three bags high and requiring approximately 4,000 sq. ft. of storage space. Despite the late start in planting this season, the hemp plants still achieved sufficient size to produce the anticipated quantity of biomass. It is expected that in 2019, planting will begin June 1st giving the hemp an addition 30-45 days of growing time. This will produce much larger plants, resulting in significantly larger quantities of biomass.
Further Processing
The Partners acquired a hammermill to complete the next level of processing, prior to the biomass going for extraction of the cannabinoids. Processing will begin shortly, once electrical work is complete to run the hammermill. This next level of processing will not only prepare the biomass for extraction of cannabinoids, but will also reduce the storage space requirements by more than 50% as the bulk of the plants is reduced in size.
Extraction
The Partners are currently exploring opportunities to joint venture with others that have expertise in the cannabinoid extraction business, so that an extraction facility can be set up onsite to process this year’s harvest. Biomass is currently selling for between US$3.00 and US$4.00 per pound. By taking the biomass to the next level of processing, further value will be created.
MCOA is a corporation which participates in: (1) product research and development of legal hemp-based consumer products under the brand name “hempSMART™”, that targets general health and well-being; (2) an affiliate marketing program to promote and sell its legal hemp-based consumer products containing CBD; (3) leasing of real property to separate business entities engaged in the growth and sale of cannabis in those states and jurisdictions where cannabis has been legalized and properly regulated for medicinal and recreations use; and, (4) the expansion of its business into ancillary areas of the legalized cannabis and hemp industry, as the legalized markets and opportunities in this segment mature and develop.
About Our hempSMART Products Containing CBD
The United States Food and Drug Administration (FDA) has not recognized CBD as a safe and effective drug for any indication. Our products containing CBD derived from industrial hemp are not marketed or sold based upon claims that their use is safe and effective treatment for any medical condition as drugs or dietary supplements subject to the FDA’s jurisdiction.
About Global Hemp Group Inc.
Global Hemp Group Inc. (CSE: GHG) (OTC: GBHPF) (FSE: GHG), is focused on a multi-phased strategy to build a strong presence in the industrial hemp industry in both Canada and the United States. The Company is headquartered in Vancouver, British Columbia, with hemp cultivation operations in New Brunswick and Oregon. The first phase of this strategy is to develop hemp cultivation with the objective of extracting cannabinoids (CBD, CBG, CBN & CBC) and creating a near term revenue stream that will allow the Company to expand and develop successive phases of the strategy. The second phase of the plan will focus on the development of value-added industrial hemp products utilizing the processing of the whole hemp plant, as envisioned in the Company’s Hemp Agro-Industrial Zone (HAIZ) strategy.
Forward Looking Statements
This news release contains “forward-looking statements” which are not purely historical and may include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities and words such as “anticipate”, “seek”, intend”, “believe”, “estimate”, “expect”, “project”, “plan”, or similar phrases may be deemed “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects, the future U.S. and global economies, the impact of competition, and the Company’s reliance on existing regulations regarding the use and development of cannabis-based products. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-12G, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission. For more information, please visit www.sec.gov.
For more information, please visit the Company’s websites at:
Posted by AGORACOM-JC
at 8:20 AM on Tuesday, November 27th, 2018
Announced the signing of a non-binding term sheet to create a joint-venture to formulate, develop and deliver cannabinoid derived therapeutics for a number of indications
Altus has three distinct drug delivery technologies that will provide Tetra with significant strategic advantages over the competition.
Seeks joint venture with Altus Formulation Inc. – a drug formulation and development company with patented technologies
ORLEANS, Ontario, Nov. 27, 2018 — Tetra Bio-Pharma Inc. (“Tetra†or “TBPâ€), (TSX VENTURE: TBP) (OTCQB: TBPMF), and Altus Formulation Inc. (“Altusâ€) today announced the signing of a non-binding term sheet (“Term Sheet“) to create a joint-venture to formulate, develop and deliver cannabinoid derived therapeutics for a number of indications. Altus has three distinct drug delivery technologies that will provide Tetra with significant strategic advantages over the competition. These include IntellitabTM abuse deterrent technology, FlexitabTM breakable sustained release tablet technology and SmartCelleTM nano-technology. SmartCelle’s ability to enhance the solubility of our THC and CBD products permits increased oral absorption and enables parenteral delivery. All platforms are protected by patents in force globally.
The Proposed Joint-Venture will provide Tetra Bio-Pharma with:
Increased intellectual property protection for products developed under the joint venture;
Access to abuse deterrent technology to minimize non-medical use of cannabinoids;
An enhanced development pipeline addressing new therapeutic areas;
Opportunities for disease-appropriate delivery including intranasal and intravenous delivery; and
Increased oral drug absorption with immediate and extended release products.
Dr. Guy Chamberland, CEO and CSO of Tetra Bio-Pharma stated, “We are extremely excited about the creation of this joint venture as Altus brings many advantages to the table that will benefit our patients, their care providers and add tremendous value to the products being developed together. Their drug delivery technology will significantly strengthen our intellectual property portfolio.â€
The White House Executive Office of the President of the United States along with several U.S. Federal agencies are encouraging pharmaceutical manufacturers to develop abuse-deterrent technologies. The Altus intellectual property will allow Tetra to bring formulations containing THC to market with a product label that clearly indicates its abuse-deterrence feature.
“This will be a major breakthrough for marketing THC drugs with opioid reduction claims at a time when society and the medical community are battling the epidemic abuse of opioids,†said Dr. Chamberland.
“We were highly impressed by Tetra’s science-driven approach to cannabinoid research and their proven ability to develop valuable medicines in this largely untapped new space,†said Dr. Damon Smith, CEO of Altus Formulation. “We greatly look forward to working with them and to bringing a range of life-changing new products to our patients.â€
About Altus Formulation Inc.
Altus Formulation is a Quebec based drug formulation and development company using its proprietary and patent protected drug delivery technologies to generate novel, differentiated and cost effective new products for its partners and their patents. With a focus on safer to use formulations, Altus’ technologies also include SmartCelle technologies for intravenous or oral delivery of low solubility large and small molecules.
About Tetra Bio-Pharma Inc. Tetra Bio-Pharma (TSX-V: TBP) (OTCQB: TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and development with a Health Canada approved, and FDA reviewed, clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. The Company has several subsidiaries engaged in the development of an advanced and growing pipeline of Bio Pharmaceuticals, Natural Health and Veterinary Health Products containing cannabis and other medicinal plant-based elements. With patients at the core of what we do, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-looking statements Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company’s research and development strategies, the success of this joint venture, the ability to obtain orphan drug status, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing of clinical trials, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. While no definitive documentation has yet been signed by the parties and there is no certainty that such documentation will be signed. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.
For further information, please contact Altus Formulation Inc.
Damon Smith
CEO
514-883-3447
For further information, please contact Tetra Bio-Pharma Inc.
Robert Bechard
Executive Vice-President Corporate Development and Licensing
514-817-2514 [email protected]
Media Contact
energi PR
Carol Levine
514-288-8500 ext. 226 [email protected]
Posted by AGORACOM-JC
at 9:09 AM on Monday, November 26th, 2018
Dr. Guy Chamberland, CEO and CSO of Tetra Bio-Pharma will be travelling to Washington, D.C. today for individual meetings with six high-ranking U.S. Senators.
Meetings, scheduled for November 26th and 27th, have a mutually beneficial purpose, namely expanding Tetra’s existing work with Health Canada and the FDA in the United States as well as briefing the Senators on Tetra Bio-Pharma’s unique approach which combines the traditional methods of medicinal cannabis use with the supporting scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies.
ORLEANS, Ontario, Nov. 26, 2018 – Tetra Bio-Pharma Inc., a leader in cannabinoid-based drug discovery and development (TSX VENTURE: TBP) (OTCQB: TBPMF), is pleased to update the market that Dr. Guy Chamberland, CEO and CSO of Tetra Bio-Pharma will be travelling to Washington, D.C. today for individual meetings with six high-ranking U.S. Senators.
The meetings, scheduled for November 26th and 27th, have a mutually beneficial purpose, namely expanding Tetra’s existing work with Health Canada and the FDA in the United States as well as briefing the Senators on Tetra Bio-Pharma’s unique approach which combines the traditional methods of medicinal cannabis use with the supporting scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies.
Tetra Bio-Pharma is the only company in North America, in addition to GW Pharmaceuticals, to work with both the FDA and Health Canada on clinical trial programs investigating cannabis and cannabinoid-based products for medical use. Tetra is currently recruiting patients for several clinical trials, including advanced cancer pain and a head to head trial investigating cannabis versus fentanyl in the treatment of breakthrough cancer pain, with the ultimate goal of reducing opioid use.
About Tetra Bio-Pharma Tetra Bio-Pharma (TSX-V: TBP) (OTCQB: TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and development with a Health Canada approved, and FDA reviewed, clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. The Company has several subsidiaries engaged in the development of an advanced and growing pipeline of Bio Pharmaceuticals, Natural Health and Veterinary Products containing cannabis and other medicinal plant-based elements. With patients at the core of what we do, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-looking statements Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company’s research and development strategies, including the ability to obtain orphan drug status, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing of clinical trials, the timing and outcomes of regulatory or intellectual property decisions, the success of the products mentioned above and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. While no definitive documentation has yet been signed by the parties and there is no certainty that such documentation will be signed. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.
For further information, please contact Tetra Bio-Pharma Inc.
Robert (Bob) Bechard
Executive Vice President, Corporate Development and Licensing
514-817-2514 [email protected]
Media Contact
energi PR
Carol Levine [email protected]
514-288-8500 ext. 226
